Ontorpacept

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118) -fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity[1].

Product Specifications

CAS Number

[2131089-46-6]

Product Name Alternative

TTI-621

UNSPSC

12352203

Target

CD47

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ontorpacept.html

Purity

99.57

Solubility

10 mM in DMSO

Smiles

[Ontorpacept]

Molecular Weight

(76.43 kDa)

References & Citations

[1]Petrova PS, et al. TTI-621 (SIRPαFc) : A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23 (4) :1068-1079.